Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCALA: Alemtuzumab SC vs IV in Progressive MS
NCT02583594Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alemtuzumab in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Change from baseline in the CD3+ lymphocyte subset after alemtuzumab administration. Started Dec 2015; status: completed.
02
Drugs
alemtuzumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02583594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583594.